Board summary
Key figures
30,964
Registered population
60.3% aged 18–64
14.1%
Aged 65+
ICB 14.9% · England 17.9%
61%
Ethnic minority (non-White)
47.4% Asian · England 9.6%
70.6%
In IMD quintile 1
ICB 40.7% · England 21.0%
~20,376
Core20 residents (est.)
Resident basis; registered basis ~22,116 · see page 3
4,215
Hypertension register
+1.67% in 3 yrs · England +5.60%
345
SMI register
9.5% of Bolton (LAD)'s
593
COPD register
Reviews +0.03% in 3 yrs
Forecast to 2030
4,462
Hypertension patients, 2030
+247 on today
67.5%
QRISK ≥20% on statins, 2030
+2.02pp over 3 yrs
2.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Cervical screening at ages 25-49 trails England.
Coverage is 52.0% (England 66.8 percent) after a -7.4% three-year change (England -1.0 percent), which could reflect unverified recall or access barriers.
Annual asthma reviews fell over three years.
Asthma review coverage is 66.0% after a -3.0% three-year change (England +4.4 percent), leaving about 600 patients without a recorded review.
Register care and control exceed national averages.
SMI blood pressure checks reach 90.2% (England 83.4 percent), alongside 72.2% hypertension control to target and 88.7% annual heart failure reviews.
Population, age and ethnicity
A younger list with 25.6% aged 0-17 sits alongside 47.4% Asian resident population
Rumworth PCN serves 30,964 registered patients across four practices. The list is younger than benchmarks: 25.6% (7,934 patients) are aged 0-17 against 23.7% in Bolton (LAD), 21.8% in NHS Greater Manchester Integrated Care Board, and 19.6% in England, while 14.1% (4,361 patients) are aged 65+ (LAD 14.7%, ICB 14.9%, England 17.9%). In associated resident areas, Census estimates indicate a 61% ethnic minority population, led by Asian / Asian British residents at 47.4% (LAD 20.1%, ICB 13.6%, England 9.6%). These resident figures describe local catchments rather than verified patient registration coding.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Bolton (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Bolton LA) | 1,923 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 55.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Bolton LA) | 958 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Bolton LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 70.6% across the PCN and varies widely between practices
Rumworth PCN has an average IMD decile of 2.6, with 70.6% of registered patients in Core20 areas, above Bolton (47.8%), NHS Greater Manchester Integrated Care Board (40.7%) and England (21.0%). A weighted practice share of 71.4% differs from the PCN figure by 0.85 percentage points. Concentration spans 38.1 pp, from 43.9% at St Helens Road Practice to 82.0% at Swan Lane Medical Centre. By volume, Swan Lane Medical Centre has 7,848 estimated Core20 patients, followed by Pikes Lane 1 with 5,622. Outreach requires balancing concentration against practice volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
345
SMI register
1.11% recorded prevalence
176
Learning disability register
0.57% recorded prevalence
17
Care homes, 551 beds
In the PCN catchment
9.8%
Provide unpaid care
Bolton (LAD), Census 2021
The PCN records 345 patients on its severe mental illness register (1.1% prevalence) and 176 on its learning disability register (0.6%), alongside 17 catchment care homes with 551 beds. Unpaid carers have a modelled ceiling estimate of 3,034 (about 3,000) using Bolton's 9.8% Census rate. Severe mental illness prevalence is 1.1% (England 1.0%), which could suggest prioritising physical health checks.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reach 90.2% (England 83.4%) and BMI recording is 87.8% (England 82.1%). Smoking cessation offers reach 93.9% (England 94.2%), including 91.3% at Pikes Lane 1 and 93.2% at St Helens Road Practice.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,215
Hypertension register
+1.67%
Register growth, 3 yrs
Bolton (LAD) +4.70% · England +5.60%
+4.76pp
BP control, under 80
≤140/90 · +5.41pp aged 80+
+247
More patients by 2030
Forecast 4,462 (14.01%)
Hypertension case-finding and control
Hypertension recorded prevalence is 13.6% (4,215 patients), below Bolton (14.8%), NHS Greater Manchester ICB (14.4%) and England (15.2%), with three-year growth of +1.7% trailing England (+5.6%). Unadjusted register gap modelling indicates a shortfall of +354 to +501 patients, although this upper bound may be overstated by a younger age profile (14.1% aged 65+ vs England 17.9%). Practice prevalence ranges from 8.4% at Shanti Medical Centre to 16.6% at St Helens Road Practice. Meanwhile, 91.2% of patients have a recent blood pressure reading and 72.2% achieve target blood pressure control, exceeding England (70.3%). Lower recorded prevalence alongside strong control could indicate robust delivery while case finding could prioritise trailing practices.
Lipids and statins
For patients with QRISK ≥ 20%, lipid therapy uptake is 63.2%, trailing NHS Greater Manchester ICB (67.0%) and England (63.6%). For diabetic patients aged 40+ without cardiovascular disease, statin coverage fell 2.9% (England +2.1%) to 70.1% (ICB 75.7%). Fewer at-risk patients receive lipid-lowering therapy than regional comparators imply, prioritising primary prevention recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 55,155 | £1.50 | £1.94 | £1.86 | £82,732 |
| Cardiovascular (all), 2025 | 77,469 | £3.02 | £3.15 | £3.33 | £233,956 |
In 2026, the PCN prescribed 55,155 items of lipid-regulating drugs at £1.50 per item, compared with £1.81 in Bolton, £1.94 in NHS Greater Manchester ICB, and £1.86 in England, spending £19,856 less than at England's unit cost. Lower unit cost indicates lower expenditure per item, but does not establish prescribing efficiency or treatment appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−3.02%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.68%
Asthma prevalence, PCN 3-yr % change
Rumworth PCN asthma prevalence is 6.1% (England 6.6%), covering 1,756 patients. Over three years, annual asthma reviews fell 3.0% (England +4.4%) to 66.0% (England 65.7%), spanning from 55.5% at Pikes Lane 1 to 70.9% at Swan Lane Medical Centre and leaving about 600 patients unreviewed. Youth asthma prescribing is 1,722 per 1,000 (England 1,488). COPD prevalence is 1.9% (593 patients; Bolton 2.4%), with reviews at 80.8% (England 76.4%). Lower review rates could reflect unverified recall barriers testable by audit.
Cancer register and children's immunisation
Cancer prevalence is 2.5% (763 patients), below England (3.8%) and Bolton (3.2%). For childhood immunisations, 6-in-1 coverage at 12 months is 88.1%, below the 95% target by 6.9 pp. At age 5, MMR dose 1 coverage is 93.3% and dose 2 is 85.4% (a 7.9 pp PCN difference), widening to 17.7 pp at Shanti Medical Centre (82.4% vs 64.7%), consistent with unverified recall barriers testable by audit.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 with known stage), compared with 55.3% in England, with a distance of -19.4 pp to the 75.0% national ambition by 2028. Known-stage completeness was 70.8% across 16,492 registered cancers. Reaching 75.0% requires about 2,270 additional early-stage diagnoses annually across the ICB. While ICB staging reflects wider system pathways rather than PCN performance, Rumworth PCN cervical screening coverage at ages 25-49 is 52.0% (England 66.8%), after a -7.4% three-year change (England -1.0%). Lower screening coverage may delay early cancer detection, making practice recall audits a priority.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For July 2026, Bolton NHS Foundation Trust met the 62-day cancer referral to treatment standard for 69.7% of pathways, trailing the 85.0% standard by 15.3 pp and below Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust (76.8%), Northern Care Alliance NHS Foundation Trust (78.6%), NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). Conversely, Bolton achieved the 28-day faster diagnosis standard at 80.5% (standard 75.0%) and the 31-day combined treatment standard at 96.5% (standard 96.0%). Diagnostic 6+ week waits at Bolton were 19.4% for computed tomography and 25.3% for cystoscopy, whereas colonoscopy was 1.3%.
| Pathways within standard (%) | Bolton | Wrightington, Wigan and Leigh | Northern Care Alliance | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.48 | 82.80 | 75.20 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.50 | 89.04 | 94.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 69.66 | 76.78 | 78.65 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Bolton | Wrightington, Wigan and Leigh | Northern Care Alliance | England |
|---|---|---|---|---|
| MRI | 2.05 | 0.49 | 5.09 | 21.40 |
| CT | 19.40 | 7.78 | 4.10 | 9.92 |
| Echocardiography | 3.48 | 24.37 | 31.48 | 28.48 |
| Colonoscopy | 1.33 | 6.10 | 40.04 | 30.83 |
| Gastroscopy | 2.06 | 12.54 | 36.48 | 29.02 |
| All 15 DM01 tests | 15.78 | 14.36 | 15.71 | 23.14 |
| Community services activity | Bolton residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 49,315 | 573,310 |
| Referrals | 4,075 | 94,470 |
| Patients with a contact | 17,765 | 183,535 |
Community services (residents of Bolton), Jun 2026 (provisional). In June 2026, adults aged 65 and over accounted for 51.6% of community service contacts among Bolton borough residents (25,460 of 49,315 contacts). These figures reflect borough-wide resident activity rather than Rumworth PCN registered patients, but demonstrate that community healthcare provision across the local authority is heavily focused on older residents.
Practice variation and patient experience
Phone access spans 35.1 pp across practices alongside uneven vaccination and immunisation achievement
In 2025/26, clinical QOF achievement reached 98.7% at Swan Lane Medical Centre and 100.0% at Shanti Medical Centre, above England (97.1%). Conversely, vaccination and immunisation achievement fell below England (55.2%), spanning 16.3 pp from 16.6% at Pikes Lane 1 to 33.0% at Swan Lane Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| St Helens Road | 107 | 43.9 | 85.3% | 78.8% | 87.3% |
| Pikes Lane 1 | 97 | 80.1 | 60.1% | 73.8% | 87.0% |
| Swan Lane | 98 | 82.0 | 59.7% | 83.2% | 81.0% |
| Shanti | 92 | 80.8 | 50.2% | 73.8% | 68.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 measures trail England's three-year change despite strong clinical reviews
Across 25 measures, 14 trail England's three-year change from 2023 to 2025. Dementia prevalence fell 3.8% (Bolton +5.0%, England +6.0%) and stroke prevalence fell 1.2% (Bolton +1.6%, England +2.3%). Conversely, clinical reviews excelled: heart failure reviews rose 22.6% (England +8.7%) to 88.7% (England 78.5%), and severe mental illness blood pressure checks increased 8.6 pp (England +4.4 pp) to 90.2% (England 83.4%). Depression prevalence rose 14.9% (England +7.7%) to 13.0% (2,999 patients). Slower register expansion alongside high review completion could reflect unverified case-finding differences rather than routine delivery, testable by practice audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Asthma reviews
Cervical screening
Cancer register
Diabetes statin (no CVD)
Heart failure reviews
BP control, 80+
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Bolton (LAD) | Asset | PCN | Bolton (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 17 (551 beds) | n/a | Schools (catchment) | 49 | n/a |
| Children's centres | 4 | 18 | Places of worship | 34 | 144 |
| Libraries | n/a | 7 | Primary schools (LA maintained) | 12 | 61 |
| Primary academies | 5 | 32 | Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension case-finding and coding audit
Recorded prevalence is 13.6% (4,215 of 30,964 patients) against Bolton (14.8%) and England (15.2%), a modelled gap of +354 to +501. For discussion: practices could search for patients with repeated raised blood pressure readings lacking a register code and offer opportunistic checks during routine contacts. Low cost, quick to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured annual asthma review recall
Annual asthma reviews fell 3.0% from 2023 to 2025 (England +4.4%) to 66.0% of 1,756 patients, leaving 597 (about 600) unreviewed. For discussion: practices could run a standardized recall template, check inhaler prescribing alongside annual reviews, and trial after-school or flexible clinic slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Cervical screening and access outreach
Cervical screening at ages 25-49 fell 7.4% (England -1.0%) to 52.0%, below Bolton (63.9%), the ICB (65.9%) and England (66.8%). For discussion: practices could audit non-responders, adapt reminder wording for the 47.4% Asian resident catchment, and review phone triage and flexible screening slots. Moderate effort to run.
Evidence base: uptake is the delivery measure of the national cancer screening programme; distance to the acceptable and achievable standards is the outreach target.
Policy anchor: Shift 3: sickness to prevention; Eliminate cervical cancer by 2040.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored primary care communication (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation offer audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension case finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Second-dose MMR recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and access triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension case-finding and coding audit (p12) | Hypertension register · Hypertension: QOF prevalence · Registered population | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Structured annual asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 3 · Cervical screening and access outreach (p12) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) · Asian / Asian British · GPPS easy to contact the practice by phone | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
